N
Nanda Horeweg
Researcher at Erasmus University Rotterdam
Publications - 49
Citations - 3149
Nanda Horeweg is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 21 publications receiving 1885 citations. Previous affiliations of Nanda Horeweg include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Harry J. de Koning,Carlijn M. van der Aalst,Pim A. de Jong,Ernst Th. Scholten,Kristiaan Nackaerts,Marjolein A Heuvelmans,Jan-Willem J. Lammers,Carla Weenink,Uraujh Yousaf-Khan,Nanda Horeweg,Susan van 't Westeinde,Mathias Prokop,Willem P.Th.M. Mali,Firdaus A. A. Mohamed Hoesein,Peter M. A. van Ooijen,Joachim G.J.V. Aerts,Michael A. den Bakker,Erik Thunnissen,Johny Verschakelen,Rozemarijn Vliegenthart,Joan Walter,Kevin ten Haaf,Harry J.M. Groen,Matthijs Oudkerk +23 more
TL;DR: In this trial involving high-risk persons, lung-cancer mortality was significantly lower among those who underwent volume CT screening than among thoseWho underwent no screening.
Journal ArticleDOI
Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening
Nanda Horeweg,Joost van Rosmalen,Marjolein A Heuvelmans,Carlijn M. van der Aalst,Rozemarijn Vliegenthart,Ernst T. Scholten,Kevin ten Haaf,Kristiaan Nackaerts,Jan-Willem J. Lammers,Carla Weenink,Harry J.M. Groen,Peter M. A. van Ooijen,Pim A. de Jong,Geertruida H. de Bock,Willem P.Th.M. Mali,Harry J. de Koning,Matthijs Oudkerk +16 more
TL;DR: This prespecified analysis quantifies how nodule diameter, volume, and volume doubling time affect the probability of developing lung cancer within 2 years of a CT scan, and proposes and evaluates thresholds for management protocols.
Journal ArticleDOI
Detection of lung cancer through low-dose CT screening (NELSON): A prespecified analysis of screening test performance and interval cancers
Nanda Horeweg,Ernst T. Scholten,Pim A. de Jong,Carlijn M. van der Aalst,Carla Weenink,Jan-Willem J. Lammers,Kristiaan Nackaerts,Rozemarijn Vliegenthart,Kevin ten Haaf,Uraujh Yousaf-Khan,Marjolein A Heuvelmans,Erik Thunnissen,Matthijs Oudkerk,Willem P.Th.M. Mali,Harry J. de Koning +14 more
TL;DR: Lung cancer screening in the NELSON trial yielded high specificity and sensitivity, with only a small number of interval cancers, which could be used to improve screening algorithms.
Journal ArticleDOI
Characteristics of Lung Cancers Detected by Computer Tomography Screening in the Randomized NELSON Trial
Nanda Horeweg,Carlijn M. van der Aalst,Erik Thunnissen,Kristiaan Nackaerts,Carla Weenink,Harry J.M. Groen,Jan-Willem J. Lammers,Joachim G.J.V. Aerts,Ernst T. Scholten,Joost van Rosmalen,Willem P.Th.M. Mali,Matthijs Oudkerk,Harry J. de Koning +12 more
TL;DR: Despite stringent criteria for a positive screening, an increasing length of screening interval, and few female participants, the screening strategy of the NELSON trial resulted in a favorable cancer stage distribution at diagnosis, which is essential for the effectiveness of this screening strategy.
Journal ArticleDOI
Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial
Nanda Horeweg,Carlijn M. van der Aalst,Rozemarijn Vliegenthart,Yingru Zhao,Xueqian Xie,Ernst T. Scholten,Willem P.Th.M. Mali,Erik Thunnissen,Carla Weenink,Harry J.M. Groen,Jan-Willem J. Lammers,Kristiaan Nackaerts,Joost van Rosmalen,Matthijs Oudkerk,Harry J. de Koning +14 more
TL;DR: The screening strategy yielded few positive and false-positive scans with a reasonable positive predictive value and risk calculations for a follow-up period of 5.5 years aid clinicians in counselling candidates for lung cancer screening with low-dose computed tomography.